The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the ...

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that ...

ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –– ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) ...

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the stock, ...

The company also has two phase 2 trials ongoing of gene therapies for Danon disease, an X-linked disorder leading to severe heart disease, and pyruvate kinase deficiency (PKD), a blood disorder ...

Normal 0.2%-2% 0%-0.9% 0.5%-2.5% ...

Sometimes, people with iron deficiency anemia don't respond to treatment with iron supplementation and may go months to years with little to no improvement in anemia. This can happen if the dose is ...